• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

More Than Half of US Approved Drugs Developed by Collaborating Companies

Article

Pharmaceutical Executive

According to the Tufts Center for the Study of Drug Development R&D Management Report, more than half of all new drugs approved in the US between 2000 and 2011 were developed by companies that collaborated in one form or another with other entities.

According to the Tufts Center for the Study of Drug Development R&D Management Report, more than half of all new drugs approved in the US between 2000 and 2011 were developed by companies that collaborated in one form or another with other entities. The report is based on insights gathered at an executive roundtable of biopharma R&D leaders. Other points included that risk-sharing partnerships are most likely to succeed when governed by a charter that ensures executive engagement, clearly delineates roles and tasks for each organization and key individuals, and defines success metrics and quality measures

Read the full story here.

Recent Videos
Related Content